Telescopes on Tap: see planets and constellations in Shreveport
'Telescopes on Tap' is an exiting new program to give individuals a basic introduction to observing planets constellations and what to look for in the night sky with or without a telescope, says event the coordinator Charlie Urban.
Shreveport Bossier Astronomical Society (SBAS) will introduce a 'new generation of smart telescopes which are rapidly changing the learning curve for beginning astronomers. You have to see this to believe it.'
When asked about his why, Urban said, 'I believe you'll understand the answer when you look through one of our telescopes for the first time and see the moons of Jupiter or the Hercules Great Globular Cluster, a brilliant cluster of thousands of stars gravitationally bound together. Maybe it will hit you when you look through a telescope and see another galaxy millions of light years away from us or the colors of a brilliant nebula.'
The program will feature astronomy trivia and prizes presented by the current president, Dr. Cran Lucas of LSUS. And if weather permits they will end the evening with stargazing.
The event will be located at Great Raft Brewing, 1251 Dalzell Street, Shreveport. Patrons must be 21 and over to attend.
The Strawberry Moon for 2025 will occur on June 11, 2025.
SBAS notes 'the full moon on June 11 is not officially full until 2:44 am Central Time, however it will be most beautiful at moonrise as it comes up over the horizon at about 8:15 pm. This will be difficult to see in town so the best spot would be in an open area with an unobstructed view to the east. The Bossier Refuge is a beautiful spot but watch out for mosquitoes. This will be when it is big and colorful and will make a beautiful 'horizon shot'.'
Urban says, this marks the full moon during June, traditionally named the Strawberry Moon because of the strawberry harvest that occurs around this time.
For SBAS's latest updates, follow them via social media.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
2 days ago
- Forbes
A ‘Planet Parade,' A ‘Black Moon' And A Meteor Shower: The Night Sky In August 2025
August is one of the best months of the year for stargazing, and 2025 is no exception. Whether you're scanning the eastern sky at dusk or venturing out before sunrise, there's something to see almost every night. The Perseids return, the Milky Way arches high overhead, and a rare 'planet parade' delivers four bright objects in the morning twilight. Here's everything you need to know about the night sky in August 2025: 1. A Full 'Sturgeon Moon' When: dusk on Friday and Saturday, August 8-9 Where: eastern horizon This month's full moon will occur early on Aug. 9, but both Aug. 8 and Aug. 9 will offer dramatic moonrises. Look east shortly after sunset to watch the sturgeon moon rise, appearing a lovely orange color. 2. A Conjunction Of Venus And Jupiter When: before dawn on Tuesday, Aug. 12 Where: east-northeast horizon In a rare planetary pairing, Venus and Jupiter will be separated by just one degree in the pre-dawn sky. This is a striking sight for the naked eye, with the two brightest planets close together, just above the eastern horizon an hour before sunrise. 3. Perseid Meteor Shower Peaks When: around midnight, August 12-15 Where: northeast to overhead The Perseids reach their maximum overnight on Aug. 12-13 evening, but a 91%-lit gibbous moon will wash out all but the brightest. For the best chance, head out before midnight and keep your back to the moon. Better still, wait until Aug. 15, when the night sky will be much darker, and there will still be an elevated rate of meteors. 4. A Planet Parade When: one hour before sunrise, Sunday to Wednesday, August 17–20 Where: eastern sky For four consecutive mornings, Jupiter, Venus and Mercury form a graceful arc in the pre-dawn sky. The waning crescent moon moves past them each morning, getting slimmer each day. The highlight comes Aug. 20 when a 9% crescent moon sits next to Venus. 5. Milky Way At Its Best When: after astronomical twilight, all month Where: southeast to the zenith August's moonless evening sky — from Aug. 16-26 — brings some of the clearest views of the Milky Way for northern observers. On moonless nights, trace its arc through the Summer Triangle stars high in the southeast and down to the galactic core near the constellations Scorpius and Sagittarius in the south. Do whatever you can to escape light pollution, using a light pollution map or staying overnight in an International Dark Sky Place. 6. A 'Black Moon' When: Saturday, Aug. 23 Where: all-sky Today's new moon has a special name — a seasonal 'black moon,' the third new moon in a season of four. Although not visible itself, its presence means an entire night of dark, moonless night skies ideal for stargazing, astronomy and astrophotography. 7. Venus And The Beehive Cluster When: before dawn on Sunday, Aug. 31 Where: east-northeast sky Look east an hour before sunrise to find brilliant Venus. Nearby, through binoculars, you'll spot the faint but pretty Beehive Cluster (M44). This open cluster in the constellation Cancer is one of the most beautiful sights in the night sky — especially when paired with a bright planet. Wishing you clear skies and wide eyes.
Yahoo
2 days ago
- Yahoo
Existing NASA Spacecraft Could Intercept the Weird Interstellar Object Cruising Into Our Star System
Earlier this month, astronomers noticed a mysterious object speeding toward the inner solar system from outside of our star system. It's an exceedingly rare occurrence, marking only the third confirmed interstellar object to have ventured into our solar system, all of which have been detected since 2017. Harvard astronomer and alien hunter Avi Loeb was quick to raise the tantalizing — albeit admittedly far-fetched — possibility that the object, dubbed 3I/ATLAS, could have been an alien probe sent to us by an intelligent civilization. And now, in a twist right out of Stanley Kubrick's 1968 "2001: A Space Odyssey," he's suggesting a way that we could use an existing spacecraft to intercept the object's path to test that very hypothesis. In a yet-to-be-peer-reviewed paper, the researcher argued that NASA's Juno spacecraft, which was designed to study Jupiter and launched in 2011, could get eerily close to 3I/ATLAS by March 14, 2026. Juno would have to apply a thrust of 1.66 miles per second on September 14, 2025, Loeb calculated, to intercept the mysterious object's path. "The close encounter of 3I/ATLAS to Jupiter provides a rare opportunity to shift Juno from its current orbit around Jupiter to intercept the path of 3I/ATLAS at its closest approach to Jupiter," he wrote in a new blog post about the proposal. While it's technically not a rendezvous — the object's "excessively high hyperbolic speed" wouldn't allow for such a meeting — Juno's arsenal of scientific instruments "can all be used to probe the nature of 3I/ATLAS from a close distance," Loeb argued. Whether the spacecraft, which has been soaring through space for 14 years now, would have enough fuel to even pull off such a stunt remains unclear. But Loeb argues it could "rejuvenate Juno's mission and extend its scientific lifespan beyond" the potential intercept some eight months from now. The news comes as scientists are still racing to get a better sense of 3I/ATLAS' exact nature. Last week, the recently inaugurated Vera C. Rubin Observatory in Chile had a closer look, finding that the object is roughly seven miles wide, making it the largest interstellar object ever spotted. The prevailing and most widely accepted theory suggests that 3I/ATLAS is a comet, with previous observations supporting the idea that its coma, or surrounding cloud of ice, dust, and gas, was anywhere up to 15 miles across. The Vera C. Rubin observations identified large amounts of dust and water ice surrounding its solid nucleus, as detailed in a July 17 preprint, further adding evidence that it's a comet. Yet many questions surrounding its origin remain a mystery. Some researchers believe it came from our galaxy's "thick disk," a dense layer that features chemically distinct populations of stars. Other researchers suggest it could be around three to 11 billion years old, dating it back to the earliest days of the Milky Way. It seems unlikely that NASA will find Loeb's suggestion compelling enough to fire up Juno's thrusters for an intercept. But it's an extremely rare opportunity to finally get a close glimpse of an interstellar visitor nonetheless — so hopefully they're at least checking his math to see if it's possible. More on 3I/ATLAS: Scientist Suggests Tests to See if Large Object Headed Toward Earth Could Be an Alien Spacecraft Solve the daily Crossword
Medscape
5 days ago
- Medscape
Nontargeted Hepatitis C Screening Yields More Diagnoses
TOPLINE: Nontargeted hepatitis C virus (HCV) screening in emergency departments (EDs) was superior to targeted screening for identifying new HCV infections in a prospective randomized screening trial. However, only a small proportion of diagnosed patients achieved sustained virologic response at 12 weeks, emphasizing the need for better HCV treatment models. METHODOLOGY: A prospective, multicenter, randomized DETECT HCV clinical trial was conducted at three urban EDs in the US, involving 147,498 adult patients (median age, 41 years; 51.5% men) with diverse racial demographics (42.3% Black, 20.9% Hispanic, and 32.2% White). clinical trial was conducted at three urban EDs in the US, involving 147,498 adult patients (median age, 41 years; 51.5% men) with diverse racial demographics (42.3% Black, 20.9% Hispanic, and 32.2% White). From November 2019 to August 2022, 73,847 patients (50.1%) were randomized to undergo nontargeted HCV screening (HCV testing offered regardless of risk). Among the 73,651 patients (49.9%) randomized to targeted HCV screening (testing offered on the basis of risk assessment), 23,400 (31.8%) were identified as having increased risk. The primary outcome was a newly diagnosed HCV infection with detectable RNA and no known prior HCV diagnosis. Secondary outcomes included repeat diagnoses; HCV test offer, acceptance, and completion rates; HCV genotype and fibrosis staging; components of the HCV care continuum; and 18-month all-cause mortality. TAKEAWAY: Nontargeted screening resulted in significantly more new HCV diagnoses than targeted screening (154 vs 115; relative risk [RR], 1.34; P = .02). Nontargeted HCV screening yielded higher testing rates than targeted screening, with 3.1 times more participants in the nontargeted group being offered testing (89.0% vs 28.5%; P < .001), a higher percentage accepting testing (22.4% vs 9.7%; P < .001), and 2.1 times more participants completing the test (13.4% vs 6.3%; P < .001). Differences in linkage to care remained nonsignificant between the groups (19.5% vs 24.3%; P = .37), with similar rates of treatment initiation (15.6% vs 17.4%; P = .74), treatment completion (12.3% vs 12.2%; P > .99), sustained virologic response at 12 weeks (9.1% vs 9.6%; P > .99), and all-cause mortality at 18 months (5.2% vs 4.3%; P > .99). Among 269 newly diagnosed patients, the 112 (41.6%) with ongoing risk — such as injection drug use — had lower linkage to care (16.1% vs 25.5%; P = .06), lower completion of direct-acting antiviral treatment (5.4% vs 17.2%; P = .004), and lower sustained virologic response (5.4% vs 12.1%; P = .06) than those without recent injection drug use. IN PRACTICE: "This multicenter randomized clinical trial determined a nontargeted screening approach was superior to targeted screening for identifying new HCV infections among patients seen in three urban EDs. The substantial decrease in patients who went from diagnosis to SVR12 [sustained virologic response at 12 weeks] highlights an urgent need for innovative models of HCV treatment," the authors concluded. SOURCE: The study was led by Jason Haukoos, MD, MSc, Department of Emergency Medicine, Denver Health, Denver. It was published online on July 09, 2025, in JAMA. LIMITATIONS: The generalizability of the study outcomes was limited by the inclusion of only three EDs experienced in infectious disease screening. Changes in ED workflows, screening implementation, and the HCV care continuum during the COVID-19 pandemic likely contributed to delays in secondary outcomes. The study was further limited by the exclusion of a large number of ED visits due to high acuity or lack of consent, potential misclassification bias, and the inability to draw clear inferences from the HCV care continuum and secondary outcomes. DISCLOSURES: The study was funded by the National Institute on Drug Abuse. Rothman reported receiving grants from the Gilead Sciences FOCUS program and the Baltimore City Health Department during the conduct of the study. Additional disclosures are noted in the original article. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
